Advertisement
Skip to Content

Alterity Therapeutics Ltd PRNAF Stock Quote

| Rating as of

PINX: PRNAF

Last close prices updated as of Jan 26, 2023, 10:23 AM EST | USD
  • Last Close 0.0078
  • Sector Healthcare
  • Industry Biotechnology
  • Investment Style Small Value
  • Day Range < 0.01  –  < 0.01
  • Year Range < 0.01  –  0.03
  • Market Cap 18.7736 Mil
  • Volume / Avg 25,000.0 /  15,280.0
  • Price / Sales 770.38
  • Price / Book 0.75
  • Forward Div Yield
  • Trailing Div Yield

Morningstar‘s Stock Analysis PRNAF

Valuation
Currency in
Is it the right time to buy or sell?
Is it the right time to buy or sell?

1-Star Price

INVESTOR

5-Star Price

INVESTOR

Economic Moat

INVESTOR

About Quantitative Ratings

Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.

Unlock Our Full Analysis With Morningstar Investor

Key Statistics PRNAF

Company Profile PRNAF

Business Description

Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.

Contact
460 Bourke Street, Level 3
Melbourne, VIC, 3000, AUS
Industry Biotechnology
Employees 12

FAQs for Alterity Therapeutics Ltd Stock

No. PRNAF does not currently have a forward dividend yield.
Dividend yield allows investors, particularly those interested in dividend-paying stocks, to compare the relationship between a stock’s price and how it rewards stockholders through dividends. The formula for calculating dividend yield is to divide the annual dividend paid per share by the stock price.

Learn more about dividend yield.

PRNAF’s market cap is 18.77 Mil.
Market capitalization is calculated by taking a company’s share price and multiplying it by the total number of shares. It’s often used to measure a company’s size. In the Morningstar Style Box, large-cap names account for the largest 70% of U.S. stocks, mid-cap names account for the largest 70–90%, and small-cap names are the remaining 10% of companies.

Learn more about market capitalization.

PRNAF’s stock style is Small Value.
Style is an investment factor that has a meaningful impact on investment risk and returns. Style is calculated by combining value and growth scores, which are first individually calculated.

High-growth stocks tend to represent the technology, healthcare, and communications sectors. They rarely distribute dividends to shareholders, opting for reinvestment in their businesses. More value-oriented stocks tend to represent financial services, utilities, and energy stocks. These are established companies that reliably pay dividends.

Learn more about style.

PRNAF’s beta can be found in Trading Information at the top of this page.
A stock’s beta measures how closely tied its price movements have been to the performance of the overall market.

Compare PRNAF’s historical performance against its industry peers and the overall market.